Weill Cornell Medicine researchers and the TB Drug Accelerator have received two grants totaling $6.8 million from the Bill & Melinda Gates Foundation to study tuberculosis drug development.
A new study reveals that beyond providing a convenient way to store DNA in a tight space, the 3D organization of noncoding gene regulators in chromatin contributes to the control of key cell identity programs in early embryonic development.
AAP NYC architecture faculty Dana Getman and Steven Garcia and students in their fall studio not only asked how to keep pace with New York City's need for more affordable housing but also how to better the lives of people who live in the homes they design and the future they build.
A preclinical study has shown that colorectal pre-cancerous lesions known as serrated polyps, and the aggressive tumors that develop from them, depend on the ramped-up production of cholesterol, which points to the possibility of using cholesterol-lowering drugs to prevent or treat such tumors.
When Dead & Company came to Cornell in May for a benefit concert commemorating the Grateful Dead’s famed “Cornell ’77” show, it drew thousands to Barton Hall. The March announcement of the show was the most-viewed Chronicle story of 2023.
A clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found remaining on the anti-obesity drug tirzepatide promoted additional weight loss and preserved improvements in metabolic and cardiovascular health.
An intercampus collaboration that aims to provide digital health care tools to pregnant refugee women, who are at elevated risk for pregnancy complications but often afraid to seek medical care, has been awarded a National Academy of Medicine Catalyst Prize.
A preclinical study by Weill Cornell Medicine investigators shows that a specific human genetic variant of a receptor that stimulates insulin release may help individuals be more resistant to obesity.